(Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results